

9 October 2026

Proposed Consolidation of Capital

Melbourne, Australia – Alcidion Group Limited (ASX: ALC) (**‘Alcidion’** or the **‘Company’**) advises that it intends to undertake a consolidation of its issued capital on a 1 to 10 basis (**Consolidation**), subject to receiving shareholder approval at the Company’s Annual General Meeting to be held on 12 November 2026.

The Consolidation is intended to simplify Alcidion’s capital structure by reducing the number of shares on issue to a level that the Board considers more proportionate to the Company’s scale and more readily comparable with relevant listed peers.

Alcidion currently has approximately 1.35 billion ordinary shares and approximately 26.7 million performance rights on issue. Following the Consolidation, the Company expects to have approximately 135 million ordinary shares and approximately 2.7 million performance rights on issue.

The Board also considers that the Consolidation may improve price granularity. At the current share price, the minimum ASX price increment represents a relatively large percentage movement in the price of an Alcidion share. Following the Consolidation, the equivalent price increment is expected to represent a smaller percentage movement, which may assist more orderly price discovery.

No change in underlying value

The Consolidation is a mechanical adjustment to the number of shares on issue. It does not, of itself:

- Change the Company’s market capitalisation, underlying value, assets, liabilities, cash position, strategy or operations.
- Change a shareholder’s proportional ownership interest in the Company, subject only to the treatment of fractional entitlements.
- Raise capital or dilute shareholders.
- Represent a forecast or assurance as to the future market price, liquidity, volatility or performance of Alcidion shares.

For example, a shareholder holding 100,000 shares at an assumed price of \$0.10 per share, with a total holding value of \$10,000, would following the Consolidation hold 10,000 shares at an assumed price of approximately \$1.00 per share, with the same total holding value of \$10,000, before any normal market movements.

The market price of Alcidion shares following the Consolidation will continue to be determined by normal market trading and may rise or fall.

Performance rights and fractional entitlements

In accordance with ASX Listing Rules 7.21 and 7.22, all performance rights currently on issue will be consolidated in the same ratio as ordinary shares.

Any fractional entitlement to a share or performance right arising from the Consolidation will be rounded up to the nearest whole number.

In summary, the Consolidation changes the number of shares and the quoted price per share. It does not, by itself, change the value of the Company or the value of a shareholder's total investment.

Indicative timetable

If shareholder approval is obtained, the Consolidation is expected to be implemented in accordance with the indicative timetable below.

Event	Date
Notice of Meeting despatched along with ASX Appendix 3A.3 and announcement of Consolidation (including the effective date)	9 October 2026
Shareholder approval at Annual General Meeting. Company notifies ASX that the consolidation is approved - Effective date of Consolidation (Day 0)	12 November 2026
Last day for trading pre-Consolidation securities (Day 1)	13 November 2026
Trading in reorganised securities commences on a deferred settlement basis (Day 2)	16 November 2026
Record Date for Consolidation. Last day for Company to register transfers on a pre-Consolidation basis (Day 3)	17 November 2026
Registration of securities on a post-Consolidation basis. First day to send new Holding Statements (Day 4)	18 November 2026
Deferred settlement trading ends. Last day to update register and send notice to all shareholders (and notification to ASX that this has occurred) (Day 8)	24 November 2026
Normal trading in reorganised securities commences (Day 9)	25 November 2026

Subject to the Listing Rules, the timetable above may be changed at the discretion of the Board or as required by the ASX.

For further information on the Consolidation, please refer to the Alcidion Group Notice of Annual General Meeting released to the ASX today.

ENDS

Authorised for ASX release by the Company Secretary of Alcidion Group Limited.

For further information, please contact: investor@alcidion.com

About Alcidion

Alcidion Group Limited has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver clinical decision support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across three established markets — Australia, New Zealand and the United Kingdom — serving hospitals and healthcare organisations at scale, with further geographical expansion planned.

With over 25 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2026